If you have lost weight on a GLP-1 medicine like Mounjaro or Wegovy, the question that matters most is rarely "how do I lose more?" It is "how do I keep this off?" That is the right question to be asking, and the honest answer is that maintenance is its own phase of treatment with its own plan — not the automatic reward for having reached a goal weight.
Here is the short version. Weight regain after stopping GLP-1 medication is common and well documented in trials, because the appetite hormones the drug was quietening go back to their old settings. Keeping weight off usually means one of two things: staying on a lower "maintenance" dose under clinical supervision, or coming off the medicine gradually while you lock in the eating, protein, muscle and monitoring habits that hold your new weight in place. Neither is a failure. Both are legitimate medical strategies, and the best one depends on you.
This guide walks through what actually happens to your body when treatment stops, what the evidence says about regain, how to build a maintenance phase that lasts, and how to think about the decision to continue or taper. It is general information, not personal medical advice — any change to your medication should always be made with your prescriber.
Why weight comes back when the medicine stops
Obesity behaves like a chronic condition, not a one-off problem you fix and forget. Your body defends a "set point" — a weight it treats as normal and works to return to. It does this through hormones: ghrelin from the stomach signals hunger, leptin from fat cells signals fullness, and the hypothalamus in the brain reads both to decide how hungry you feel and how much energy you burn.
GLP-1 (glucagon-like peptide-1) medicines work by mimicking a gut hormone that tells the brain you are full and slows how quickly the stomach empties. That is what turns down the constant background pull toward food that many people describe as "food noise." When the medicine leaves your system, that signal fades and appetite typically climbs back toward where it was before.
This is not a character flaw and it is not the treatment "not working." It is the expected physiology. The clearest evidence comes from the STEP 1 extension study: participants who stopped semaglutide (Wegovy) regained roughly two-thirds of the weight they had lost within a year of stopping, and much of the cardiometabolic improvement reversed with it (Wilding et al., Diabetes, Obesity and Metabolism, 2022). Understanding that number up front changes how you plan — because it tells you the medicine is managing an ongoing condition, not curing it.
What "maintenance" actually means
Maintenance is the phase where the goal shifts from losing to holding. It has two common shapes:
- Continued treatment at a maintenance dose. Many people stay on their medicine long term, sometimes at the dose that got them to goal, sometimes at a lower one, to keep appetite regulated. In licensed use, GLP-1 medicines are approved for ongoing weight management, not a fixed course.
- A supervised taper off the medicine. Others step down gradually while relying on the habits built during treatment to hold their weight. This works best when the lifestyle scaffolding is genuinely in place first.
There is no single correct route. What matters is that the decision is made deliberately, with a prescriber, rather than by running out of pens or stopping abruptly.
| Staying on a maintenance dose | Tapering off the medicine | |
|---|---|---|
| Best suited to | People whose appetite and weight climb quickly without it | People who have embedded strong eating, protein and activity habits |
| Main advantage | Appetite regulation is maintained, lowering regain risk | No ongoing medication or cost |
| Main challenge | Ongoing cost and continued clinical review | Higher risk of regain if habits slip |
| Clinical oversight | Regular reviews to confirm it remains appropriate | Structured step-down and follow-up |
Whichever path you take, stopping or changing dose without guidance is the one option to avoid — your clinical team can manage the transition far more safely than a sudden halt.
Building a maintenance plan that holds
The medicine buys you a window in which food is quieter and change is possible. Maintenance is about what you build inside that window. Four things do most of the heavy lifting.
Protect your muscle. When you lose weight — with or without medication — some of the loss is lean tissue, and muscle is what keeps your resting metabolism up. Prioritising protein at each meal and doing regular resistance training (two to three sessions a week is a sensible target for most people) protects that muscle and makes your new weight easier to defend. This matters most on the way down, so ideally you start it during the losing phase, not after.
Anchor your eating pattern. Use the calmer appetite to establish meals you can genuinely repeat: enough protein and fibre to stay full, portions that fit your day, and a structure that survives a busy week. The aim is a pattern you would keep even if the medicine were gone.
Keep monitoring — lightly. People who maintain weight loss tend to keep a light touch on the data: periodic weigh-ins, a rough sense of intake, and an early plan for the first few pounds of regain rather than waiting for a stone. Small, early corrections are far easier than large, late ones.
Sleep, stress and alcohol. Short sleep and high stress both push hunger hormones in the wrong direction. Alcohol adds calories, can worsen GLP-1 side effects like nausea, and loosens food decisions — if a side effect like nausea troubles you, you can report it through the MHRA Yellow Card scheme (covered in the safety section below). None of these need to be perfect — but they are levers you control.
If you are earlier in the journey and still choosing a treatment, our comparison of Mounjaro versus Wegovy and the weight-loss injections overview explain how the two medicines differ in practice.
Deciding whether to continue or come off
There is no universal deadline for stopping. Because obesity is a relapsing condition, long-term treatment is a legitimate choice for many people, in the same way that ongoing medication is normal for blood pressure or cholesterol. The right decision depends on your regain risk, how well your habits are holding, side effects, cost, and your own preferences.
A few honest prompts to bring to a review:
- Has my appetite and eating pattern genuinely changed, or is the medicine still doing most of the work?
- If I have tried reducing dose before, what happened?
- Am I managing side effects well, or are they a reason to reconsider?
- Is continued treatment sustainable for me financially?
None of these have a "right" answer. They exist to make the choice deliberate. Your prescriber can help you weigh them and, if you do come off, design a taper rather than a cliff-edge.
A note on safety
Sustainable use means using these medicines within their licence and with proper oversight. In the UK, Mounjaro (tirzepatide) and Wegovy (semaglutide) are prescription-only medicines, supplied only after an online consultation and clinical assessment by a prescriber — never bought without one. Their licence covers a BMI of 30 or above, or 27 or above with a weight-related condition such as type 2 diabetes or high blood pressure.
The common side effects — nausea, reflux and other digestive changes — usually appear during dose increases and settle over time, which is why Mounjaro is titrated from a 2.5mg starting dose with increases of 2.5mg no sooner than every four weeks, up to a maximum of 15mg. Rarer but more serious risks include pancreatitis (inflammation of the pancreas) and gallbladder problems, and these medicines are not suitable for everyone — for example, they are not used in pregnancy or where there is a personal or family history of certain thyroid cancers. These points are covered in more depth in our guide to Mounjaro and Wegovy side effects and how to manage them. If you experience a side effect, you can report it through the MHRA (Medicines and Healthcare products Regulatory Agency) Yellow Card scheme at yellowcard.mhra.gov.uk.
How it works at The Weight Clinic
The Weight Clinic is a UK online pharmacy registered with the General Pharmaceutical Council, led by Superintendent Pharmacist Andrew Lane, with prescribing by Pharmacist Independent Prescriber Fatma Al Sibahi and clinical content reviewed by Pharmacist Independent Prescriber Ali Al Sibahi. Every request is reviewed by a prescriber against your medical history — there is no algorithm-only "yes," and no subscription or membership fee just to speak to a clinician.
If you are already losing weight and thinking about the maintenance phase, or weighing up whether to continue, that is exactly the kind of conversation a review is for. And if you are just starting out, the eligibility check is free, with Mounjaro from £125 a month and Wegovy from £80 for your first month (£115 standard, with £35 off your first order using code NEWME), and no subscription to sign up to.
Check your eligibility in a few minutes — there is no cost and no obligation to proceed.
Frequently asked questions
Will I regain the weight if I stop the injections? Some regain is common, because appetite hormones return to their pre-treatment settings when the medicine stops. In the STEP 1 extension study, people who stopped semaglutide regained around two-thirds of the weight they had lost within a year (Wilding et al., 2022). How much you regain depends heavily on the habits you have built and whether you taper gradually with support. Results vary from person to person.
Do I have to take Mounjaro or Wegovy forever? No — but you should decide with a prescriber rather than by default. Because obesity is a chronic, relapsing condition, some people stay on a maintenance dose long term, while others taper off once eating, protein and activity habits are firmly in place. Both are valid; the wrong move is stopping abruptly on your own.
How much weight is realistic, and how do I keep it? In the SURMOUNT-1 trial, tirzepatide (Mounjaro) at 15mg produced an average of about 22.5% body-weight loss over 72 weeks (New England Journal of Medicine, 2022); in STEP 1, semaglutide (Wegovy) at 2.4mg averaged about 14.9% over 68 weeks (New England Journal of Medicine, 2021). Keeping it off depends on protecting muscle with protein and resistance training, maintaining a repeatable eating pattern, and catching small regains early. Individual results vary.
Can I switch to a lower dose to maintain instead of stopping completely? Often, yes — a lower maintenance dose is a recognised strategy for keeping appetite regulated with less medication. Whether it suits you depends on how your appetite and weight respond, so it is a decision to make with your prescriber, who can adjust and monitor safely.
Is it better to taper off slowly than stop suddenly? A gradual, supervised step-down gives you the chance to see how your appetite responds and to reinforce habits before the medicine is fully gone, rather than facing the full return of hunger at once. Never change your dose without guidance from your clinical team.
Does alcohol affect maintenance? It can. Alcohol adds calories, can worsen GLP-1 side effects such as nausea, and tends to loosen food decisions. You do not have to be teetotal, but keeping it moderate and staying well hydrated makes the maintenance phase easier.
Frequently asked questions
Will I regain the weight if I stop the injections?
Some regain is common, because appetite hormones return to their pre-treatment settings when the medicine stops. In the STEP 1 extension study, people who stopped semaglutide regained around two-thirds of the weight they had lost within a year (Wilding et al., 2022). How much you regain depends heavily on the habits you have built and whether you taper gradually with support. Results vary from person to person.
Do I have to take Mounjaro or Wegovy forever?
No — but you should decide with a prescriber rather than by default. Because obesity is a chronic, relapsing condition, some people stay on a maintenance dose long term, while others taper off once eating, protein and activity habits are firmly in place. Both are valid; the wrong move is stopping abruptly on your own.
How much weight is realistic, and how do I keep it?
In the SURMOUNT-1 trial, tirzepatide (Mounjaro) at 15mg produced an average of about 22.5% body-weight loss over 72 weeks; in STEP 1, semaglutide (Wegovy) at 2.4mg averaged about 14.9% over 68 weeks. Keeping it off depends on protecting muscle with protein and resistance training, maintaining a repeatable eating pattern, and catching small regains early. Individual results vary.
Can I switch to a lower dose to maintain instead of stopping completely?
Often, yes — a lower maintenance dose is a recognised strategy for keeping appetite regulated with less medication. Whether it suits you depends on how your appetite and weight respond, so it is a decision to make with your prescriber, who can adjust and monitor safely.
Is it better to taper off slowly than stop suddenly?
A gradual, supervised step-down gives you the chance to see how your appetite responds and to reinforce habits before the medicine is fully gone, rather than facing the full return of hunger at once. Never change your dose without guidance from your clinical team.
Does alcohol affect maintenance?
It can. Alcohol adds calories, can worsen GLP-1 side effects such as nausea, and tends to loosen food decisions. You do not have to be teetotal, but keeping it moderate and staying well hydrated makes the maintenance phase easier.
